Bacthera AG, a joint-venture contract manufacturer, has received authorisations from regulatory authorities in Switzerland and Denmark to begin supplying active ingredients to developers of live biotherapeutic products, a new therapeutic modality. The supply will be used for clinical trials of candidate therapies, and eventually for their commercialisation.
According to the consultancy Roots Analysis, more than 85 microbiome-based live biotherapeutic products were in preclinical and clinical development in mid-2020 with demand for manufacturing capacity rising.